WEBULL
News
NAMS
35.26
-1.65%
-0.59
NewAmsterdam Pharma Price Target Raised to $37.00/Share From $30.00 by Goldman Sachs
Dow Jones · 4d ago
NewAmsterdam Pharma Is Maintained at Neutral by Goldman Sachs
Dow Jones · 4d ago
Goldman Sachs Maintains Neutral on NewAmsterdam Pharma Co, Raises Price Target to $37
Benzinga · 4d ago
NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs
TipRanks · 4d ago
Weekly Report: what happened at NAMS last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at NAMS last week (1117-1121)?
Weekly Report · 11/24 10:21
Weekly Report: what happened at NAMS last week (1110-1114)?
Weekly Report · 11/17 10:20
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating
Seeking Alpha · 11/16 15:30
Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
TipRanks · 11/11 08:15
RBC Capital Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks · 11/10 12:19
Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TipRanks · 11/10 12:19
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Emergent Biosolutions (EBS) and Ginkgo Bioworks Holdings (DNA)
TipRanks · 11/10 11:30
Weekly Report: what happened at NAMS last week (1103-1107)?
Weekly Report · 11/10 10:18
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
TipRanks · 11/10 01:57
January 2028 Options Now Available For NewAmsterdam Pharma (NAMS)
NASDAQ · 11/07 16:01
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 11/07 15:01
NewAmsterdam Pharma Reports Q3 2025 Financial Results
TipRanks · 11/07 06:53
RBC Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)
TipRanks · 11/07 01:49
NewAmsterdam Pharma Is Maintained at Outperform by RBC Capital
Dow Jones · 11/06 16:32
NewAmsterdam Pharma Price Target Raised to $44.00/Share From $39.00 by RBC Capital
Dow Jones · 11/06 16:32
More
Webull provides a variety of real-time NAMS stock news. You can receive the latest news about NewAmsterdam Pharma Company N.V through multiple platforms. This information may help you make smarter investment decisions.
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.